
==== Front
BMC Med
BMC Med
BMC Medicine
1741-7015
BioMed Central London

3644
10.1186/s12916-024-03644-0
Correction
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Han Ruoshuang 12
Guo Haoyue 1
Shi Jinpeng 1
Zhao Sha 1
Jia Yijun 1
Liu Xiaozhen 1
Liu Yiwei 1
Cheng Lei 3
Zhao Chao 3
Li Xuefei 3
http://orcid.org/0000-0003-0073-6619
Zhou Caicun caicunzhoudr@yeah.net

1
1 grid.412532.3 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
2 https://ror.org/04wjghj95 grid.412636.4 Department of Oncology, The First Affiliated Hospital of Army Medical University, Chongqing, People’s Republic of China
3 grid.412532.3 Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
20 9 2024
20 9 2024
2024
22 405© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmc Correction : BMC Med 22, 174 (2024)

https://doi.org/10.1186/s12916-024-03389-w

The original article [1] mistakenly omitted Equal Contribution attribution for the first four authors – Ruoshang Han, Haoyue Guo, Jinpeng Shi, and Sha Zhao – due to an error from the production team that handled the manuscript.

The Equal Contribution attribution has since been restored.

Ruoshuang Han, Haoyue Guo, Jinpeng Shi and Sha Zhao contributed equally to this work.
==== Refs
Reference

1. Han R Guo H Shi J Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer BMC Med 2024 22 174 10.1186/s12916-024-03389-w 38658988
Han R, Guo H, Shi J, et al. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. BMC Med. 2024;22:174. 10.1186/s12916-024-03389-w.38658988
